4.8 Article

Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy

期刊

NANO TODAY
卷 36, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2020.101023

关键词

Cancer immunotherapy; Biomaterials; Drug delivery; Immune checkpoint blockade; Immune-engineering

资金

  1. National Natural Science Foundation of China [61435010, 61575089, 82003036]
  2. Science and Technology Innovation Commission of Shenzhen, China [KQTD2015032416270385, JCYJ20150625103619275, KQJSCX20180321164801762, JCYJ20180507181817604]
  3. China Postdoctoral Science Foundation [2018M643364, 2019M663377]
  4. PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China [2018A030310040]

向作者/读者索取更多资源

Therapeutic targeting of the immune system, including immunotherapy and nanotechnology, presents a promising approach for treating various cancers. While immunotherapeutics have limitations, nanotechnology offers unique opportunities to enhance therapeutic efficacy through precision targeting and controlled drug release. Combining these two modalities could provide synergistic efficacy in cancer treatment.
Therapeutic targeting of the immune system, including chimeric antigen receptor-T cell therapy, immune checkpoint blockade therapy, neoantigen vaccines, and small molecule modulators emerges as one of the most effective therapeutic modalities for treating various cancers in human patients. However, clinical efficacies of these immunotherapeutics are generally modest and only a minority of cancer patients benefit from immunotherapy. Further, broad adverse effects, lack of reliable biomarkers, tumour relapses, drug resistance, and metastasis have become increasingly recognized concerns, which may restrain their clinical utility. Unlike most other anticancer strategies, nanomaterial-based therapeutics parade unique and distinct biological features to achieve precision targeting, local drug release, and enhancing therapeutic efficacy. As long-term and sustained release of immunotherapeutics are necessary for enhancing anticancer immunity, nanotechnology ensures accumulation of immunotherapuetics, controlled release, and precision delivery of immune drugs. Combination of these two therapeutic modalities would provide synergistic efficacy for effectively treating various cancers in human patients. To the best of our knowledge, the concept of combination therapy employing nanomaterials and immunotherapy has been overlooked. In this article, we discuss possible mechanisms underlying nano-immunotherapy and unique opportunities of nanotechnology in synergizing cancer treatment. (C) 2020 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据